Trevi Therapeutics Analyst Ratings
Trevi Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 234.73% | Needham | → $8 | Reiterates | Buy → Buy |
| 05/12/2023 | 234.73% | Needham | → $8 | Reiterates | Buy → Buy |
| 04/18/2023 | 234.73% | Needham | → $8 | Reiterates | → Buy |
| 04/12/2023 | 151.05% | B. Riley Securities | → $6 | Initiates Coverage On | → Buy |
| 03/17/2023 | 234.73% | Needham | → $8 | Reiterates | → Buy |
| 03/14/2023 | 192.89% | JonesTrading | → $7 | Initiates Coverage On | → Buy |
| 11/22/2022 | 151.05% | SVB Leerink | → $6 | Initiates Coverage On | → Outperform |
| 11/11/2022 | 234.73% | Needham | $10 → $8 | Maintains | Buy |
| 06/30/2022 | 318.41% | Needham | $8 → $10 | Maintains | Buy |
| 05/25/2022 | 318.41% | Oppenheimer | → $10 | Initiates Coverage On | → Outperform |
| 03/29/2022 | 318.41% | Aegis Capital | → $10 | Initiates Coverage On | → Buy |
| 11/11/2021 | 234.73% | Needham | $10 → $8 | Maintains | Buy |
| 08/13/2021 | 318.41% | Needham | $12 → $10 | Maintains | Buy |
| 08/14/2020 | 276.57% | SVB Leerink | $8 → $9 | Maintains | Outperform |
| 07/13/2020 | 402.09% | Needham | $18 → $12 | Maintains | Buy |
| 06/03/2019 | 653.14% | Needham | → $18 | Initiates Coverage On | → Buy |
| 06/03/2019 | 527.62% | BMO Capital | → $15 | Initiates Coverage On | → Outperform |
| 06/03/2019 | 736.82% | Stifel | → $20 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/11/2023 | 234.73% | 尼德姆 | → 8 美元 | 重申 | 購買 → 購買 |
| 05/12/2023 | 234.73% | 尼德姆 | → 8 美元 | 重申 | 購買 → 購買 |
| 04/18/2023 | 234.73% | 尼德姆 | → 8 美元 | 重申 | → 購買 |
| 2023 年 12 月 4 日 | 151.05% | B. 萊利證券 | → 6 美元 | 啓動覆蓋開啓 | → 購買 |
| 03/17/2023 | 234.73% | 尼德姆 | → 8 美元 | 重申 | → 購買 |
| 03/14/2023 | 192.89% | JonesTrading | → 7 美元 | 啓動覆蓋開啓 | → 購買 |
| 11/22/2022 | 151.05% | SVB Leerink | → 6 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 11/11/2022 | 234.73% | 尼德姆 | 10 美元 → 8 美元 | 維護 | 購買 |
| 06/30/2022 | 318.41% | 尼德姆 | 8 美元 → 10 美元 | 維護 | 購買 |
| 05/25/2022 | 318.41% | 奧本海默 | → 10 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 2022 年 3 月 29 日 | 318.41% | 宙斯盾資本 | → 10 美元 | 啓動覆蓋開啓 | → 購買 |
| 11/11/2021 | 234.73% | 尼德姆 | 10 美元 → 8 美元 | 維護 | 購買 |
| 08/13/2021 | 318.41% | 尼德姆 | 12 美元 → 10 美元 | 維護 | 購買 |
| 2020 年 8 月 14 日 | 276.57% | SVB Leerink | 8 美元 → 9 美元 | 維護 | 跑贏大盤 |
| 07/13/2020 | 402.09% | 尼德姆 | 18 美元 → 12 美元 | 維護 | 購買 |
| 06/03/2019 | 653.14% | 尼德姆 | → 18 美元 | 啓動覆蓋開啓 | → 購買 |
| 06/03/2019 | 527.62% | BMO 資本 | → 15 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 06/03/2019 | 736.82% | Stifel | → 20 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Trevi Therapeutics (TRVI)?
Trevi Therapeutics（TRVI）的目標價格是多少？
The latest price target for Trevi Therapeutics (NASDAQ: TRVI) was reported by Needham on August 11, 2023. The analyst firm set a price target for $8.00 expecting TRVI to rise to within 12 months (a possible 234.73% upside). 8 analyst firms have reported ratings in the last year.
Needham於2023年8月11日公佈了Trevi Therapeutics（納斯達克股票代碼：TRVI）的最新目標股價。這家分析公司將目標股價定爲8.00美元，預計TRVI將在12個月內升至12個月內（可能上漲234.73％）。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for Trevi Therapeutics (TRVI)?
分析師對Trevi Therapeutics（TRVI）的最新評級是多少？
The latest analyst rating for Trevi Therapeutics (NASDAQ: TRVI) was provided by Needham, and Trevi Therapeutics reiterated their buy rating.
Trevi Therapeutics（納斯達克股票代碼：TRVI）的最新分析師評級由Needham提供，Trevi Therapeutics重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Trevi Therapeutics (TRVI)?
Trevi Therapeutics（TRVI）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Trevi Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Trevi Therapeutics was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Trevi Therapeutics的高管和客戶交談以及聽取業績電話會議）後得出了股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Trevi Therapeutics的最後一次評級是在2023年8月11日提交的，因此你應該預計下一個評級將在2024年8月11日左右公佈。
Is the Analyst Rating Trevi Therapeutics (TRVI) correct?
分析師對 Trevi Therapeutics (TRVI) 的評級正確嗎？
While ratings are subjective and will change, the latest Trevi Therapeutics (TRVI) rating was a reiterated with a price target of $0.00 to $8.00. The current price Trevi Therapeutics (TRVI) is trading at is $2.39, which is within the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Trevi Therapeutics（TRVI）評級得到了重申，目標股價爲0.00美元至8.00美元。Trevi Therapeutics（TRVI）目前的交易價格爲2.39美元，在分析師的預測區間內。